secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001753926-24-001759
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve reincorporation to Nevada and name change to Channel Therapeutics; board adds $500k to buyback
--------------------------------------------------------------------------------

- Proposal 4 approved: reincorporation from Delaware to Nevada and renaming to Channel Therapeutics Corp. (2.6M for, 2.3K against, 929.7K abstain).
- Board authorizes amendment to repurchase plan: adds $500k (total $750k) and extends termination to June 30, 2025.
- Proposal 1: all five director nominees elected (Todd Davis, Ezra Friedberg, Francis Knuettel II, Dr. Richard Malamut, Chia-Lin Simmons).
- Proposal 2: amendment to 2023 Equity Incentive Plan increasing authorized shares approved (3.5M for).
- Proposal 5: Marcum LLP ratified as independent auditor for FY2024 (3.9M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624001759/0001753926-24-001759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624001759/g084503_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer